Section
This article reviews a robust UK trial assessing hypertonic saline and carbocisteine in bronchiectasis, revealing no significant reduction in pulmonary exacerbations over 52 weeks, highlighting the need for continued research on mucoactive
Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effecti
A randomized trial demonstrates that low-dose apixaban for 12 months significantly lowers symptomatic recurrent VTE risk after provoked events with enduring risk factors, with minimal major bleeding.
A recent trial comparing adaptive, algorithm-driven telephone support with static monthly coaching found no significant difference in long-term weight loss maintenance, highlighting complexities in obesity treatment and the need for refined
High uric acid is linked to several diseases, and many avoid meat fearing purines. However, some vegetarian foods are high in purines too. Understanding these can help better manage uric acid levels and prevent complications like gout.
This phase I randomized study shows rapirosiran, an RNAi therapeutic targeting HSD17B13, is safe and effectively reduces liver HSD17B13 mRNA in patients with metabolic dysfunction-associated steatohepatitis (MASH).
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
A phase Ib/IIa trial demonstrated that HEC88473, a novel GLP-1/FGF21 dual agonist, is generally safe, effectively reduces liver fat, and improves glycemic and lipid profiles in MASLD patients with type 2 diabetes within five weeks of treatm
AZD2693, a liver-directed antisense oligonucleotide, safely reduces PNPLA3 expression and liver fat in homozygous PNPLA3 148M carriers with metabolic dysfunction-associated steatohepatitis, signaling promise for precision treatment in this
This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Lanifibranor, a pan-PPAR agonist, significantly reduces liver fat and improves insulin sensitivity at multiple tissue sites in type 2 diabetes patients with MASLD, offering a new therapeutic avenue to address underlying metabolic dysfunctio
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
The pilot PARTUM trial demonstrates the feasibility of a large-scale multi-national randomized study assessing low-dose aspirin versus placebo for postpartum venous thromboembolism prevention in moderate-risk individuals, supporting further
In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.
The DANFLU-2 trial demonstrates that high-dose influenza vaccine reduces cardiovascular and cardiorespiratory hospitalizations compared to standard-dose in adults ≥65 years, with similar benefits across subgroups including heart failure and
Dietary nitrate supplementation alters age-related oral microbiome changes, enhancing nitric oxide bioavailability and reducing blood pressure in older adults, highlighting a novel mechanism for vascular health improvement.
Long COVID patients exhibit distinct mitochondrial bioenergetic impairments, with altered ATP synthase function correlating with clinical symptoms and quality of life, implicating mitochondrial dysfunction in its pathogenesis.
Low FT3 and FT4 levels in chronic critical illness correlate with increased 90-day mortality, supporting thyroid function as a valuable prognostic marker and guide for early clinical intervention.
A study reveals that inhaling molecular hydrogen for 60 minutes enhances fat oxidation at rest in healthy women, potentially offering metabolic benefits, particularly for those with higher body fat percentages.
